about
Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virusNon-avian animal reservoirs present a source of influenza A PB1-F2 proteins with novel virulence-enhancing markers.Antiviral therapy of influenza.Insights into the interaction between influenza virus and pneumococcusThe immune profile associated with acute allergic asthma accelerates clearance of influenza virusThe co-pathogenesis of influenza viruses with bacteria in the lung.Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumoniaNonstructural protein 1 (NS1)-mediated inhibition of c-Abl results in acute lung injury and priming for bacterial co-infections: insights into 1918 H1N1 pandemic?Viral suppressors of the RIG-I-mediated interferon response are pre-packaged in influenza virionsPlanning for an influenza pandemic: thinking beyond the virus.Vaccines against pandemic influenza: what can be done before the next pandemic?Preparing for the next influenza pandemic.Acute Lung Injury Results from Innate Sensing of Viruses by an ER Stress PathwayGlycosylation Analysis of Engineered H3N2 Influenza A Virus Hemagglutinins with Sequentially Added Historically Relevant Glycosylation Sites.The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesisDoes Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza?The Role of Punctuated Evolution in the Pathogenicity of Influenza Viruses.PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology.Seroprevalence of seasonal and pandemic influenza A viruses in domestic cats.Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulenceGlycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A VirusEffect of 1918 PB1-F2 expression on influenza A virus infection kinetics.Preventing and treating secondary bacterial infections with antiviral agentsMotivating factors for high rates of influenza vaccination among healthcare workers.Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant miceNo evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodiesImpaired wound healing predisposes obese mice to severe influenza virus infection.Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.The age distribution of mortality due to influenza: pandemic and peri-pandemic.Molecular signatures of virulence in the PB1-F2 proteins of H5N1 influenza viruses.Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae.A step closer to meeting the threat of avian influenza.Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae.The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired PneumoniaInfluence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired PneumoniaContribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complicationsAre toilet seats a vector for transmission of methicillin-resistant Staphylococcus aureus?Mathematical model of a three-stage innate immune response to a pneumococcal lung infection
P50
Q24600337-7BFA949E-25F8-421D-B3CE-5348371D2786Q30151193-F628F0FF-3E8F-4226-8D3B-6317DB39A151Q30350565-9AA04A0D-BB35-45AF-84A4-466E542AEF82Q30355570-870364A1-74AD-49C6-A798-92FADEDE13D2Q30358384-A46D3569-ECEB-4A12-9300-A07362C493CAQ30359731-619A2052-E9D9-4299-9005-216BA4BF55F9Q30365855-B1227A14-2346-4D11-BD77-204D0EE7AE54Q30368379-1BD7D1CC-C563-41F1-84D8-5CA6AC8BA853Q30369504-CB15D77F-9FB5-4BBD-9179-BE830429232CQ30371469-70AB5192-41AC-4D11-B615-B52FC317B4E0Q30372308-366AE017-C40E-49D8-9D23-109BE6CE4A70Q30372312-E3308E3B-7A0A-45D1-8A97-5AC1A9BC5997Q30375413-96D50234-EE2A-4BF1-8920-1A5E2127883CQ30377052-686DE8AC-1B5A-43DE-AC54-DF4FAF8753C5Q30381642-27ECA884-25C9-4CA3-9FDA-D32A6EE11CF3Q30384213-51D4A5B5-FEFA-4DF0-ACD7-32157BE1B751Q30388541-5C083B3C-9A2C-4643-AE57-403BFBAEEFE5Q30391867-4E7BF308-5E04-48B5-BC11-D2DB7F16406EQ30394246-76321929-F91C-4291-888C-ACF32692B08FQ30394678-6A6792B0-E518-4BCC-AFD5-F2099AD275D9Q30394731-8A36545B-E0E1-4C3C-A364-141409690F14Q30399806-8D6EB338-F97E-4C1B-810F-FFA2E95D6F97Q30400455-35CA3EF5-DB89-418F-93B8-0F1696509B6DQ30401260-4F2DE42D-57D2-4CA9-BDA6-74E8ED6211C9Q30404168-2D82402D-C5FE-4B45-BB9F-B3E21FBBEED3Q30406363-BD33F273-C3A4-4C7D-84A2-EECAA3761C43Q30407561-2D817FC9-ACC3-4320-94FD-C4CDF1A42637Q30410362-FD7C80E9-87BA-48F1-BF18-771ED3D2CB9BQ30410465-1C5BF8DA-1331-417A-9DEF-4E67B8D03B5DQ30424688-EAF8AD5E-4531-476D-9772-A9CD7E7F76E4Q30428356-81E0D416-3A1C-4C7B-AB86-2C3F0BE94496Q30429002-A744C4E3-5D3C-45C8-8E92-315AFC849D92Q33257256-25508E62-3775-46C2-A855-C58B31BE6FE9Q33279810-30DB94B1-4445-4BD2-9290-F18DCE86E584Q33554796-C40C2483-719C-4D0D-8AC7-77A43E998D83Q33629039-7F760BE5-8175-4436-AD8F-C06F4B812EF1Q33629579-3F33E950-1382-4BBF-B23E-74296573532AQ33769373-BF14BB70-5541-44F5-A01D-60CC187B544FQ34245804-BD191042-90CF-41DC-BCB5-0ED676B1D6FDQ34733562-81574CB1-2FF8-410A-A480-65BE1B565B2E
P50
name
Jonathan A McCullers
@en
type
label
Jonathan A McCullers
@en
prefLabel
Jonathan A McCullers
@en